Literature DB >> 8151595

Herpes zoster infections in systemic lupus erythematosus: risk factors and outcome.

L E Kahl1.   

Abstract

OBJECTIVE: To determine factors that influence the frequency and outcome of herpes zoster infection in patients with systemic lupus erythematosus (SLE).
METHODS: In this case-central retrospective study, patients with a history of zoster infection were identified from our computerized database of 348 patients with SLE. Medical records were reviewed to establish activity of SLE at the time of zoster, as well as complications of the zoster infection.
RESULTS: Fifty-five episodes of zoster occurred among 47 (13.5%) patients, at a rate of 16 episodes/1000 patient-years of followup. Dissemination occurred in 6 episodes (11%), and was more frequent during immunosuppressive therapy [odds ratio (OR) = 4.0]. Bacterial superinfection occurred in 5 (9%), resulting in one death from sepsis, and was increased among patients receiving prednisone > or = 60 mg daily (OR = 4.1). Compared to those without zoster, patients with zoster were significantly more likely to have previously had serious disease manifestations including nephritis, thrombocytopenia or hemolytic anemia, and to have received treatment with cyclophosphamide (all p < or = 0.05). However, 65% of zoster episodes occurred during mild or inactive SLE, when the majority of patients were receiving less than 20 mg prednisone daily and no immunosuppressive therapy.
CONCLUSION: Herpes zoster infections occur at increased frequency among patients with SLE compared to the general population, and carry significant morbidity. Patients who have had severe manifestations of lupus are at greatest risk of zoster, though not necessarily at the time of disease flare or immunosuppressive therapy. If disease activity allows, a reduction in prednisone dosage may reduce the risk of bacterial superinfection during zoster episodes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8151595

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  21 in total

1.  Incidence of herpes zoster in patients with giant cell arteritis: a population-based cohort study.

Authors:  Valentin S Schäfer; Tanaz A Kermani; Cynthia S Crowson; Gene G Hunder; Sherine E Gabriel; Steven R Ytterberg; Eric L Matteson; Kenneth J Warrington
Journal:  Rheumatology (Oxford)       Date:  2010-07-13       Impact factor: 7.580

Review 2.  Combination therapy: the risks of infection and tumor induction.

Authors:  D E Yocum
Journal:  Springer Semin Immunopathol       Date:  2001

Review 3.  Complications of cyclophosphamide therapy.

Authors:  C A Langford
Journal:  Eur Arch Otorhinolaryngol       Date:  1997       Impact factor: 2.503

4.  Longitudinal analysis of varicella-zoster virus-specific antibodies in systemic lupus erythematosus: No association with subclinical viral reactivations or lupus disease activity.

Authors:  C Rondaan; C C van Leer; S van Assen; H Bootsma; K de Leeuw; S Arends; N A Bos; J Westra
Journal:  Lupus       Date:  2018-04-18       Impact factor: 2.911

5.  The case for Zostavax vaccination in systemic lupus erythematosus.

Authors:  Abigail R Cogman; Eliza F Chakravarty
Journal:  Vaccine       Date:  2013-06-03       Impact factor: 3.641

Review 6.  Vaccination of patients with autoimmune inflammatory rheumatic diseases.

Authors:  Johanna Westra; Christien Rondaan; Sander van Assen; Marc Bijl
Journal:  Nat Rev Rheumatol       Date:  2014-12-09       Impact factor: 20.543

7.  Feasibility and validity were demonstrated of an online case-control study using the prototype of recent-onset systemic lupus erythematosus.

Authors:  Timothy McAlindon; Jun Wang; Margaret Formica; Ashley Kay; Hocine Tighiouart; Christine Chaisson; Jeremiah Fletcher
Journal:  J Clin Epidemiol       Date:  2008-03-14       Impact factor: 6.437

8.  Herpes Zoster as the Presenting Manifestation of Systemic Lupus Erythematosus (SLE): A Rare Case Report.

Authors:  Arshna Qureshi; Debasish Chaudhury
Journal:  J Clin Diagn Res       Date:  2016-03-01

9.  Evaluation of a patient self-stratification methodology to identify those in need of shielding during COVID-19.

Authors:  Elizabeth Reilly; Sarah Skeoch; Sarah Hardcastle; John D Pauling; Megan Rowe; Tehseen Ahmed; Andrew Allard; Bashaar Boyce; Ellie Korendowych; Chloe Lapraik; William Tillett; Raj Sengupta
Journal:  Clin Med (Lond)       Date:  2020-09-11       Impact factor: 2.659

10.  Herpes zoster vaccination in SLE: a pilot study of immunogenicity.

Authors:  Joel M Guthridge; Abigail Cogman; Joan T Merrill; Susan Macwana; Krista M Bean; Tiny Powe; Virginia Roberts; Judith A James; Eliza F Chakravarty
Journal:  J Rheumatol       Date:  2013-09-15       Impact factor: 4.666

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.